Druvion Bio Inc.
Druvion Bio is developing a modular cell therapy platform designed to separate the engineered T-cell platform from tumor targeting—creating a path toward more adaptable, controllable and scalable CAR-T therapies.
One Cell Platform. Multiple Targets.
About Druvion Bio Inc.
Druvion Bio Inc. is pioneering the future of cancer immunotherapy through a next-generation modular universal CAR-T platform. Led by a team of renowned immuno-oncology experts, our company is dedicated to developing innovative, scalable immune cell therapies that overcome the significant limitations of traditional CAR-T approaches. We believe that transformative cancer treatments require cutting-edge science, strategic vision, and unwavering commitment to patient outcomes.
Our mission is to translate groundbreaking scientific discoveries into transformative patient treatments through strategic collaborations and rigorous development. By focusing on universal CAR-T platforms, we aim to make advanced immunotherapy more accessible, effective, and scalable for cancer patients worldwide. At Druvion Bio Inc., we are committed to advancing the field of cell therapy and establishing new standards for cancer care.
Our Platform Technologies
Universal CAR-T Platform
Our proprietary next-generation Modular CAR-T platform that overcomes traditional CAR-T limitations through innovative engineering and scalable manufacturing processes, enabling broader patient accessibility and improved therapeutic outcomes.
Immune Cell Therapy Development
We develop advanced immune cell therapies designed to harness the body’s natural defense mechanisms against cancer. Our scalable approach enables customized treatments while maintaining manufacturing efficiency and therapeutic efficacy.
Strategic Collaboration Services
We partner with leading research institutions and pharmaceutical companies to accelerate the translation of cutting-edge immunotherapy science into clinical applications, fostering innovation ecosystems that drive transformative cancer treatments.